Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855365 | PMC |
| http://dx.doi.org/10.18632/oncoscience.492 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.
Med
December 2024
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Omaha, NE, USA. Electronic address:
Tumor-agnostic US Food and Drug Administration approvals are transforming oncology. They include larotrectinib/entrectinib/repotrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib/trametinib (BRAF mutations), pembrolizumab/dostarlimab (microsatellite instability), pembrolizumab (high tumor mutational burden), and trastuzumab deruxtecan (HER2 3+ expression) (all solid cancers). Pemigatinib is approved for FGFR1-rearranged myeloid/lymphoid neoplasms.
View Article and Find Full Text PDFCombination of cowpea mosaic virus (CPMV) intratumoral therapy and oxaliplatin chemotherapy.
Mater Adv
June 2024
Department of NanoEngineering, University of California San Diego, 9500 Gilman Dr, La Jolla, California 92093, USA.
Article Synopsis
- - Cowpea mosaic virus (CPMV) has shown effectiveness as an immunotherapy for tumors in preclinical and canine trials, prompting exploration of combination treatments to enhance its efficacy.
- - A study combining CPMV with the chemotherapy drug oxaliplatin significantly improved survival rates and reduced tumor size in mouse models of ovarian and melanoma cancers, outperforming each treatment alone.
- - The therapy worked by activating immune responses and modulating the tumor environment, highlighting the potential for combining CPMV with traditional chemotherapy in future clinical applications.
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab.
Drugs
December 2024
Global Clinical Development-Oncology, Merck & Co., Inc., Rahway, NJ, USA.
The accelerated approval (AA) pathway was established by the United States Food and Drug Administration (FDA) to provide earlier access to therapies for patients with serious medical conditions and unmet medical needs. Since its inception, the AA pathway has been used for novel treatments across different therapeutic areas, but most prominently in oncology, including the immune checkpoint inhibitor class. This review article describes the history of regulatory approvals for pembrolizumab, an immunotherapy agent targeting programmed death receptor-1 (PD-1), and use of the AA pathway and the corresponding regulatory decisions made by the FDA.
View Article and Find Full Text PDFHistology Agnostic Drug Development: An Updated Review.
Cancers (Basel)
October 2024
Touro University Nevada College of Osteopathic Medicine, 874 American Pacific Dr, Henderson, NV 89014, USA.
Recent advancements in oncology have led to the development of histology-agnostic therapies, which target genetic alterations irrespective of the tumor's tissue of origin. This review aimed to provide a comprehensive update on the current state of histology-agnostic drug development, focusing on key therapies, including pembrolizumab, larotrectinib, entrectinib, dostarlimab, dabrafenib plus trametinib, selpercatinib, trastuzumab deruxtecan, and reprotrectinib. We performed a detailed analysis of each therapy's mechanism of action, clinical trial outcomes, and associated biomarkers.
View Article and Find Full Text PDFRedefining pancreatic cancer management with tumor-agnostic precision medicine.
Carcinogenesis
November 2024
Early-Phase Drug Development, Sarah Cannon Research Institute, 335 24th Avenue North Suite 300, Nashville, TN 37203, United States.
Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of pancreatic cancer, the prevalence of the KRAS gene mutation is noteworthy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!